Kotaro Yuge
Kurume, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.
Journal: Nature medicine
Published: January 28, 2026
Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.
Journal: Nature medicine
Published: July 23, 2025
Ghrelin restores D1 receptor-mediated dopamine neurotransmission and enhances attentive behaviour in Mecp2 KO mice.
Journal: European journal of pharmacology
Published: June 06, 2025
Genome sequencing provides high diagnostic yield and new etiological insights for intellectual disability and developmental delay.
Journal: NPJ genomic medicine
Published: March 11, 2025
Hemizygous SMARCA1 variants cause X-linked intellectual disability.
Journal: Journal of human genetics
Published: January 27, 2025
The Development of Methods of BLOTCHIP®-MS for Peptidome: Small Samples in Tuberous Sclerosis.
Journal: Current issues in molecular biology
Published: November 17, 2024
Attenuated orexinergic signaling underlies sleep-wake problems in a Mecp2-null mouse model of Rett syndrome.
Journal: Neurobiology of disease
Published: September 05, 2024
Onasemnogene Abeparvovec Treatment after Nusinersen in an Infant with Spinal Muscular Atrophy Type 1.
Journal: The Kurume medical journal
Published: January 17, 2024
Spinal Muscular Atrophy Type I With False Negative in Newborn Screening: A Case Report.
Journal: Cureus
Published: July 24, 2023
Comparison of long-term quality of life based on surgical procedure in patients with rectal cancer.
Journal: Frontiers in oncology
Published: March 30, 2023
Gene therapy for spinal muscular atrophy is considerably effective when administered as early as possible after birth.
Journal: Molecular genetics and metabolism reports
Published: December 28, 2022
Association between cerebrospinal fluid parameters and developmental and neurological status in glucose transporter 1 deficiency syndrome.
Journal: Journal of the neurological sciences
Published: August 28, 2022
Last Updated: 09/26/2026